Polaris
is a California-based biotechnology company that develops and commercializes novel anti-cancer therapies for the treatment of cancer... Read morePolaris
is a California-based biotechnology company that develops and commercializes novel anti-cancer therapies for the treatment of cancer... Read more
News
Dec 22, 2023
BioSpace
Polaris: Polaris Group Announced the Acquisition of Genovior Biotech, Initiating Dual-Engine Growth
Dec 04, 2023
MarketScreener
Polaris: Polaris Group Initiates Phase 3 Trial: First Patient Successfully Dosed with ADI-PEG 20/Placebo plus Gemcitabine and Docetaxel for Difficult-to-Treat Leiomyosarcoma (LMS)
Nov 17, 2023
StreetInsider
Press Release: Polaris : Polaris Group Initiates Rolling Submission of Biologic License Application (BLA) for ADI-PEG 20 with U.S. FDA to Treat Malignant Pleural Mesothelioma
Aug 15, 2023
BioSpace
Polaris: Global Coalition for Adaptive Research and Polaris Group Announce Commencement of ADI-PEG 20 in GBM AGILE Trial
Jan 28, 2022
Citybizlist
Polaris: Polaris to Expand Vacaville Site with Acquisition of 15 Acres
Jan 27, 2022
Pharmaceutical Processing World
Polaris: Polaris Pharmaceuticals extends operations in Northern California
Jul 09, 2018
PharmiWeb
Polarispharma: Polaris Announces Drs. James Allison and Padmanee Sharma Joining its Scientific Advisory Board
Jun 03, 2018
PharmiWeb
Polarispharma: Polaris Group Presents Results for Phase 1 Clinical Study with its Lead Therapeutic Candidate ADI-PEG 20 Plus FOLFOX in Hepatocellular Carcinoma
May 31, 2018
WardsAuto
Polarispharma: Polaris Group Announces Treatment of First Patient in a Phase 2 Study of ADI-PEG 20 Plus Gemcitabine and Docetaxel for Soft Tissue Sarcoma
Oct 16, 2017
BioPortfolio
Polaris: Polaris Pharmaceuticals Inc Pharmaceuticals Healthcare Deals and Alliances Profile Report Updated 14092017 Prices from USD $250
Polaris Competitors
1
2
3
4
5
6
7
8
9
10